Related Experiment Video

Updated: Feb 1, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.5K

[Application of angiotensin II receptor blocker in prostate cancer]

Hiroji Uemura1, Yoshinobu Kubota

  • 1Department of Urology, Yokohama City University Graduate School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|April 8, 2009
PubMed

Insights

Angiotensin II receptor blockers (ARBs) show potential in decelerating prostate-specific antigen elevation and suppressing prostate cancer incidence. These findings suggest ARBs may possess chemopreventive properties against prostate cancer.

Area of Science:

  • Oncology
  • Pharmacology
  • Cardiovascular Research

Context:

  • Growing evidence links the renin-angiotensin system to various cancer developments.
  • Angiotensin II (Ang-II) involvement in cancer is increasingly recognized, particularly with the widespread use of AT1 receptor blockers (ARBs).
  • Previous observations noted lower cancer prevalence in hypertensive patients using angiotensin-converting enzyme inhibitors.

Purpose:

  • To explore the role of the renin-angiotensin system, specifically Ang-II, in cancer development.
  • To investigate the potential chemopreventive activity of ARBs in prostate cancer.
  • To evaluate ARB's effect on prostate-specific antigen (PSA) elevation in hormone-refractory prostate cancer.

Summary:

  • Basic and clinical data suggest that ARBs may decelerate PSA elevation, especially in hormone-refractory prostate cancer.
  • ARBs show potential in suppressing the incidence of prostate cancer.
  • The findings imply that ARBs could have a chemopreventive role in prostate cancer.

Impact:

  • Suggests a novel therapeutic or preventive strategy for prostate cancer using ARBs.
  • Highlights the potential of targeting the renin-angiotensin system for cancer chemoprevention.
  • Provides a basis for further clinical trials investigating ARBs in prostate cancer management.

More Related Videos

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples07:16

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples

Published on: March 14, 2014

14.6K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.9K

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.7K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.2K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.6K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.7K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.7K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.5K